Live Breaking News & Updates on Euromyelitis

Stay updated with breaking news from Euromyelitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Horizon Therapeutics plc: Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA (inebilizumab-cdon)

Analysis in The Journal of Neurology, Neurosurgery and Psychiatry demonstrate the direct effect of UPLIZNA on levels of sNFL and sGFAP, two key biomarkers strongly associated with NMOSD attacks ....

United States , Neuroimmunol Neuroinflamm , Rachel Vann , Orhan Aktas , Kristina Patterson , Tina Ventura , Product Communications , Exchange Commission , Department Of Neurology , Expanded Disability Status Scale , Medical Faculty , Neuromyelitis Optica Spectrum Disorder , Hepatitisb Virus , Progressive Multifocal Leukoencephalopathy , Full Prescribing Information , United States Securities , Accessed April , Scler Relat , Vice President , Chief Investor Relations Officer ,

AstraZeneca's Ultomiris approved in EU for autoimmune disease NMOSD

AstraZeneca PLC on Wednesday said the European Commission approved its drug Ultomiris in the EU for adults with autoimmune disease neuromyelitis optica spectrum disorder, known as NMOSD.

The. | May 10, 2023 ....

City Of , United Kingdom , Orhan Aktas , Marc Dunoyer , Tom Budszus , Alliance News Ltd , Alliance News , Department Of Neurology , European Commission , Alexion Pharmaceuticals , Medical Faculty , All Rights , Astrazeneca Plc Stock Exchange , Press Release , As Azn Gb0009895292 ,

AstraZeneca's Ultomiris Recommended for Marketing Authorization in EU

By Michael Susin

AstraZeneca PLC said Monday that its treatment for patients with neuromyelitis optica spectrum disorder has been recommended for marketing authorization in the European Union.. | April 3, 2023 ....

Michael Susin , European Union , European Medicines Agency , Medicinal Products , Human Use , Dow Jones , Astrazeneca Plc Stock Exchange , Press Release , Uropean Azn Gb0009895292 ,

Horizon Therapeutics plc: New Analysis of MRI Findings Show UPLIZNA (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic ....

United States , Dennis Riedl , Neuroimmunol Neuroinflamm , Tina Ventura , Bruce Cree , Ray Gordon , Rachel Vann , Product Communications , European Commission , Drug Administration , Exchange Commission , Brazilian Health Regulatory Agency , Ophthalmology Society , Horizon Therapeutics , North American Neuro Ophthalmology Society , California San Francisco Weill Institute , About Neuromyelitis Optica Spectrum Disorder , Hepatitisb Virus , Progressive Multifocal Leukoencephalopathy , Full Prescribing Information , United States Securities , Accessed April , Scler Relat , Vice President , Chief Investor Relations Officer , Media Contact ,

Horizon Therapeutics plc: New Data Suggest UPLIZNA (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines

Analyses suggest the B-cell-depleting mechanism of UPLIZNA did not interfere with important immune activity, including COVID-19 infection defenses and antibody levels from childhood vaccines Horizon ....

United States , San Diego , Dennis Riedl , Kristina Patterson , Neuroimmunol Neuroinflamm , Tina Ventura , Bruce Cree , Ray Gordon , Rachel Vann , Product Communications , Americas Committee For Treatment , European Commission , Drug Administration , Exchange Commission , Research In Multiple Sclerosis , Americas Committee , Multiple Sclerosis , Clinical Neurology , California San Francisco Weill Institute , Did Not Affect Vaccine Generated Antibodies , Neuromyelitis Optica Spectrum Disorder , Hepatitisb Virus , Progressive Multifocal Leukoencephalopathy , Full Prescribing Information , United States Securities , Accessed April ,